159 Simmons Cancer Center Grand Rounds: "The Diverse Metabolic Actions of FGF21" (101518)

Dallas, TX US
October 15, 2018

The purpose of the Simmons Cancer Center Grand Rounds is to fulfill the need to provide oncology physicians, scientists, residents, clinical fellows, and other interested individuals with the latest information and research on advances in cancer etiology, pathogenesis and therapeutics.  Eminent cancer research scholars and  physicians will be brought to the Simmons Cancer Center to discuss and disseminate this knowledge  through lectures, audio/video presentations, case studies, syllabi or other handouts, and question and answer sessions.

Target Audience

The target audience for this program is UT Southwestern faculty, physicians, residents, and fellows in Oncology, e.g., Medical, Pediatric, Surgical, Radiation and Neurological.

Learning Objectives

The overall objectives of this program are to utilize the latest cancer therapeutics in the most effective way possible for the benefit of UT Southwestern Medical Center at Dallas cancer patients.  

At the conclusion of this program, participants should be able to integrate the latest peer reviewed cancer research scholarship and knowledge into their clinical and translational research programs and translate the clinical and research experiences and knowledge of  their peers and eminent scholars into new and emerging cancer research and patient care.

Course summary
Available credit: 
  • 1.00 AMA
  • 1.00 Attendance
Course opens: 
10/15/2018
Course expires: 
10/15/2018
Event starts: 
10/15/2018 - 12:00pm CDT
Event ends: 
10/15/2018 - 1:00pm CDT
Cost:
$0.00
Add to calendar: 
UT Southwestern Medical Center
5323 Harry Hines Blvd.
NB2EEF AUDITORIUM
Dallas, TX 75390
United States

 

 

 

 

 

 

Committee member(s)

Carlos Arteaga, Professor & Director, Simmons Comprehensive Cancer Center, Internal Medicine, Office of the Dean - Southwestern Medical School

has a financial relationship (Professional Services) with ARVINAS;.
has a financial relationship (Grant Or Contract) with Pfizer;.
has a financial relationship (Professional Services) with Novartis;.
has a financial relationship (Professional Services) with Merck;.
has a financial relationship (Professional Services) with Immunomedics;.
has a financial relationship (Professional Services) with Susan G. Komen;.
has a financial relationship (Professional Services) with Daiichi Sankyo;.
has a financial relationship (Professional Services) with OrigiMed;.
has a financial relationship (Professional Services) with Athenex;.
has a financial relationship (Stock Options) with Provista;.
has a financial relationship (Professional Services) with TAIHO Oncology;.
has a financial relationship (Professional Services) with Sanofi;.
has a financial relationship (Grant Or Contract) with Lilly;.
has a financial relationship (Professional Services) with Lilly;.
has a financial relationship (Professional Services) with AstraZeneca;.
Course Director(s)

Carlos Arteaga, Professor & Director, Simmons Comprehensive Cancer Center, Internal Medicine, Office of the Dean - Southwestern Medical School

has a financial relationship (Professional Services) with Lilly;.
has a financial relationship (Professional Services) with AstraZeneca;.
has a financial relationship (Professional Services) with Sanofi;.
has a financial relationship (Grant Or Contract) with Lilly;.
has a financial relationship (Professional Services) with Novartis;.
has a financial relationship (Professional Services) with Merck;.
has a financial relationship (Professional Services) with ARVINAS;.
has a financial relationship (Grant Or Contract) with Pfizer;.
has a financial relationship (Professional Services) with Daiichi Sankyo;.
has a financial relationship (Professional Services) with Immunomedics;.
has a financial relationship (Professional Services) with Susan G. Komen;.
has a financial relationship (Professional Services) with TAIHO Oncology;.
has a financial relationship (Professional Services) with OrigiMed;.
has a financial relationship (Professional Services) with Athenex;.
has a financial relationship (Stock Options) with Provista;.
Medical director(s)

Carlos Arteaga, Professor & Director, Simmons Comprehensive Cancer Center, Internal Medicine, Office of the Dean - Southwestern Medical School

has a financial relationship (Professional Services) with OrigiMed;.
has a financial relationship (Professional Services) with Athenex;.
has a financial relationship (Stock Options) with Provista;.
has a financial relationship (Professional Services) with TAIHO Oncology;.
has a financial relationship (Professional Services) with AstraZeneca;.
has a financial relationship (Professional Services) with Sanofi;.
has a financial relationship (Grant Or Contract) with Lilly;.
has a financial relationship (Professional Services) with Lilly;.
has a financial relationship (Professional Services) with ARVINAS;.
has a financial relationship (Grant Or Contract) with Pfizer;.
has a financial relationship (Professional Services) with Novartis;.
has a financial relationship (Professional Services) with Merck;.
has a financial relationship (Professional Services) with Immunomedics;.
has a financial relationship (Professional Services) with Susan G. Komen;.
has a financial relationship (Professional Services) with Daiichi Sankyo;.
Moderator(s)

Carlos Arteaga, Professor & Director, Simmons Comprehensive Cancer Center, Internal Medicine, Office of the Dean - Southwestern Medical School

has a financial relationship (Professional Services) with Daiichi Sankyo;.
has a financial relationship (Professional Services) with Immunomedics;.
has a financial relationship (Professional Services) with Susan G. Komen;.
has a financial relationship (Professional Services) with TAIHO Oncology;.
has a financial relationship (Professional Services) with OrigiMed;.
has a financial relationship (Professional Services) with Athenex;.
has a financial relationship (Stock Options) with Provista;.
has a financial relationship (Professional Services) with Lilly;.
has a financial relationship (Professional Services) with AstraZeneca;.
has a financial relationship (Professional Services) with Sanofi;.
has a financial relationship (Grant Or Contract) with Lilly;.
has a financial relationship (Professional Services) with Novartis;.
has a financial relationship (Professional Services) with Merck;.
has a financial relationship (Professional Services) with ARVINAS;.
has a financial relationship (Grant Or Contract) with Pfizer;.
Peer reviewer(s)

Carlos Arteaga, Professor & Director, Simmons Comprehensive Cancer Center, Internal Medicine, Office of the Dean - Southwestern Medical School

has a financial relationship (Professional Services) with Merck;.
has a financial relationship (Professional Services) with ARVINAS;.
has a financial relationship (Grant Or Contract) with Pfizer;.
has a financial relationship (Professional Services) with Novartis;.
has a financial relationship (Professional Services) with Immunomedics;.
has a financial relationship (Professional Services) with Susan G. Komen;.
has a financial relationship (Professional Services) with Daiichi Sankyo;.
has a financial relationship (Professional Services) with OrigiMed;.
has a financial relationship (Professional Services) with Athenex;.
has a financial relationship (Stock Options) with Provista;.
has a financial relationship (Professional Services) with TAIHO Oncology;.
has a financial relationship (Professional Services) with AstraZeneca;.
has a financial relationship (Professional Services) with Sanofi;.
has a financial relationship (Grant Or Contract) with Lilly;.
has a financial relationship (Professional Services) with Lilly;.
Planner(s)

Carlos Arteaga, Professor & Director, Simmons Comprehensive Cancer Center, Internal Medicine, Office of the Dean - Southwestern Medical School

has a financial relationship (Professional Services) with Lilly;.
has a financial relationship (Professional Services) with AstraZeneca;.
has a financial relationship (Professional Services) with Sanofi;.
has a financial relationship (Grant Or Contract) with Lilly;.
has a financial relationship (Professional Services) with Novartis;.
has a financial relationship (Professional Services) with Merck;.
has a financial relationship (Professional Services) with ARVINAS;.
has a financial relationship (Grant Or Contract) with Pfizer;.
has a financial relationship (Professional Services) with Daiichi Sankyo;.
has a financial relationship (Professional Services) with Immunomedics;.
has a financial relationship (Professional Services) with Susan G. Komen;.
has a financial relationship (Professional Services) with TAIHO Oncology;.
has a financial relationship (Professional Services) with OrigiMed;.
has a financial relationship (Professional Services) with Athenex;.
has a financial relationship (Stock Options) with Provista;.
Speaker(s)

DAVID MANGELSDORF

has no relevant financial relationships to disclose at this time.

Available Credit

  • 1.00 AMA
  • 1.00 Attendance

Price

Cost:
$0.00
Please login or create an account to take this course.